Phase 2 Sleep Disorders Trial, Recruiting NCT05589753 Sponsor: VA Office of Research and Development Condition: Sleep Disorders
Back to Sleep Disorders

Phase 2 Sleep Disorders Trial, Recruiting

NCT05589753
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a Veteran between 18 and 89 years old
  • You have been prescribed opioid medication by a doctor

Who may not be able to join:

  • Your body mass index (a measure of body weight relative to height) is over 40 (confirm with trial site)
  • You have a heart condition that has not been treated or resolved, such as a recent heart attack, recent heart bypass surgery, or untreated irregular heartbeats
  • You have heart failure along with an unusual breathing pattern during sleep called Cheyne-Stokes respiration (confirm with trial site)
  • You currently have unstable chest pain (angina)
  • You have had a stroke recently
  • You have schizophrenia that is not being treated
  • You have an underactive thyroid that is not being treated
  • You have a seizure condition that has not been resolved
  • You have severe disease affecting your lungs, nervous system, liver, or kidneys
  • You have a psychiatric condition or PTSD that is not stable or not being treated
  • You have had a traumatic brain injury
  • You are pregnant
  • You have a significant sleep condition such as narcolepsy or parasomnia (abnormal behaviors during sleep)
  • You are not able or willing to give your formal consent to take part in the study
  • You are currently taking tramadol or suboxone/buprenorphine

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Susmita Chowdhuri, MD MS, John D. Dingell VA Medical Center, Detroit, MI

Phone: (313) 576-4464

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
2 May 2019
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Apneic threshold - a measure of breathing instability; Cerebrovascular responsiveness to carbon-dioxide; Ventilatory responsiveness; Carbon-dioxide reserve

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov